title: An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis.
abstract: BACKGROUND
  Antipsychotic medications facilitate the improvement of psychotic symptoms in patients with first-episode psychosis. Paliperidone extended-release (pali-ER), an atypical antipsychotic, was assessed for efficacy and safety in Chinese patients with first-episode psychosis.
  
  
  METHODS
  In this 8-week, open-label, single-arm, multicenter study, patients with first-episode psychosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) and a Positive and Negative Syndrome Scale (PANSS) total score ≥70 were treated with flexible-dose pali-ER tablets (3-12 mg/day). The primary efficacy endpoint was the percentage of patients with an increase of ≥8 points in Personal and Social Performance (PSP) score from baseline to day 56 (8 weeks). Secondary endpoints included reduction in PANSS total score, improvement in Clinical Global Impression-Severity score, PSP score, Subjective Well-being under Neuroleptics Scale score, and relationship between duration of untreated psychosis and PANSS or PSP. Incidences of treatment-emergent adverse events were used to evaluate safety.
  
  
  RESULTS
  Overall, 283 of 294 patients (96%) achieved a ≥8-point increase in PSP (primary endpoint, analysis set). For the secondary efficacy endpoints, 284/306 patients (93%) had a ≥30% reduction in PANSS total score; 266/306 patients (87%) achieved a ≤3 Clinical Global Impression-Severity scale score, and 218/294 patients (74%) had a PSP score ≥71. The Subjective Well-being under Neuroleptics Scale score was improved from a baseline mean of 72.7 to 94.7 at endpoint. There was a negative correlation between duration of untreated psychosis and posttreatment PSP score and a positive correlation with posttreatment PANSS total score. The most common treatment-emergent adverse events were extrapyramidal symptoms (12%), and agitation, somnolence, and xerostomia (4% each).
  
  
  CONCLUSIONS
  An 8-week, flexible-dose (3-12 mg/day) treatment with pali-ER resulted in significant improvements in psychotic symptoms and social functioning in Chinese patients with first-episode psychosis and was generally tolerable.
authors: Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People's Republic of China.
authors: TianMei
authors: T
authors: Si
authors: Fourth Military Medical University, First Hospital, Xi'an, People's Republic of China.
authors: QingRong
authors: Q
authors: Tan
authors: Shanxi Medical University, First Hospital, Shanxi, People's Republic of China.
authors: KeRang
authors: K
authors: Zhang
authors: Janssen Research and Development, Beijing, People's Republic of China.
authors: Yang
authors: Y
authors: Wang
authors: Janssen Research and Development, Beijing, People's Republic of China.
authors: Qing
authors: Q
authors: Rui
keywords: Personal and Social Performance score; first-episode psychosis; paliperidone
references: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8
references: 21315787
references: Psychopharmacology (Berl). 2002 Jun;162(1):24-8
references: 12107613
references: Acta Psychiatr Scand. 2013 Jun;127(6):442-54
references: 23298325
references: Hum Psychopharmacol. 2012 Nov;27(6):605-14
references: 24446539
references: Int Clin Psychopharmacol. 2008 Nov;23(6):343-56
references: 18854723
references: Schizophr Res. 2009 Aug;113(1):56-64
references: 19560322
references: Psychiatr Serv. 2012 Jul;63(7):719
references: 22752039
references: Schizophr Res. 2007 Feb;90(1-3):147-61
references: 17092691
references: Schizophr Res. 2007 Jul;93(1-3):117-30
references: 17466492
references: Schizophr Res Treatment. 2012;2012:764769
references: 22966444
references: Schizophr Bull. 2011 May;37(3):619-30
references: 19900962
references: J Clin Psychiatry. 2008 May;69(5):817-29
references: 18466043
references: J Clin Psychiatry. 1996;57 Suppl 9:5-9
references: 8823344
references: J Clin Psychopharmacol. 2004 Apr;24(2):220-4
references: 15206670
references: J Clin Psychiatry. 2006 Oct;67(10 ):1511-21
references: 17107241
references: Br J Psychiatry. 2007 Mar;190:237-42
references: 17329744
references: Schizophr Res. 2008 Jul;102(1-3):270-7
references: 18495437